This is a federal contract award from the Department of Veterans Affairs (VA) to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract is for the delivery of non-pet radiopharmaceuticals to support nuclear medicine diagnostic services at VA medical centers. The contract has a performance period from April 1, 2025, to March 31, 2026, with a ceiling value of $425,725.07. It is a firm-fixed-price delivery order contract, and there is no set-aside designation.
RLS (USA) Inc. is an experienced federal contractor, holding several indefinite delivery vehicle (IDV) contracts with the VA and the Defense Health Agency (DHA) for the supply of various radiopharmaceutical products, including gallium-67, fluorodeoxyglucose F-18, thallium-201, technetium-99m, and Gallium-68 Dotatate. These products are critical for nuclear medicine imaging procedures and diagnostic services provided to veterans and military personnel. The company operates 31 radiopharmacy facilities across 18 states, enabling it to efficiently deliver these time-sensitive radiopharmaceutical products to government healthcare facilities nationwide.
Generated 4/2/25, 10:11 AM